A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies.
Ribrag V, Iglesias L, De Braud F, Ma B, Yokota T, Zander T, Spreafico A, Subbiah V, Illert AL, Tan D, Santoro A, Munster PN, Suehiro Y, Wang Y, Ji DM, Chen S, Beltz K, Suenaga N, Ramkumar T, Luo F, Lai C, Wainberg ZA.
Ribrag V, et al. Among authors: ma b.
Eur J Cancer. 2024 Nov 16;216:115122. doi: 10.1016/j.ejca.2024.115122. Online ahead of print.
Eur J Cancer. 2024.
PMID: 39793445